Skip to content
lifestyle.tophustler.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
AB Science
AB Science will hold a web conference on Wednesday, October 14, 2026, from 6:00 p.m. to 7:30 p.m.
October 12, 2026
AB Science today reports its revenues for the first half of 2026 and provides an update on its activities
October 9, 2026
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection
September 29, 2026
AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs
July 10, 2026
AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
June 29, 2026
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
June 17, 2026
AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS
June 9, 2026
AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share
June 2, 2026
AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share
May 25, 2026
AB Science reports its revenues for the year 2025 and provides an update on its activities
May 24, 2026
1
2
Next Page
→